Tags

Type your tag names separated by a space and hit enter

High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study.
Clin Epidemiol. 2018; 10:159-165.CE

Abstract

Background

Statins have been linked to new-onset osteoporotic fractures (NOFs), and different statins may alter the risk for the development of NOFs.

Aim

In this study, we investigated the association between different statins and the development of NOFs.

Patients and methods

This was a longitudinal cohort study performed using data from claim forms submitted to the Taiwan Bureau of National Health Insurance, including case patients with NOFs from January 2004 to December 2013 and non-NOF subjects. We estimated the hazard ratios (HRs) of NOFs associated with statin use. Nonuser subjects served as the reference group.

Results

A total of 44,405 patients with NOFs were identified from among 170,533 patients with hyperlipidemia during the study period. The risk of developing NOFs after adjusting for age, sex, comorbidities, and concurrent medication use was lower among users of atorvastatin (HR, 0.77; 95% CI, 0.71-0.84) and rosuvastatin (HR, 0.72; 95% CI, 0.64-0.81) than among simvastatin users. Lovastatin, pravastatin, fluvastatin, and pitavastatin were not associated with the risk of developing NOFs compared with simvastatin users.

Conclusion

This study supports previous reports regarding a beneficial effect of statin use and NOF risk, but not all statins. Patients taking atorvastatin or rosuvastatin were at lower risk of developing NOFs compared with simvastatin users during the 10-year follow-up. Other statins such as pravastatin, fluvastatin, lovastatin, and pitavastatin were not associated with NOFs. This study also highlighted that high-potency statin has a dose-response effect on lower NOF risk.

Authors+Show Affiliations

Department of Pharmacy, Taoyuan Armed Forces General Hospital, Taoyuan. Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei.Department of Family Medicine and Geriatrics, Taichung Veteran General Hospital, Taichung. School of Public Health, National Defense Medical Center, Taipei.Department of Medical Research, Taichung Veterans General Hospital, Taichung.Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei.Division of Internal Cardiology, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan, Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29403315

Citation

Lin, Tsung-Kun, et al. "High-potency Statins but Not All Statins Decrease the Risk of New-onset Osteoporotic Fractures: a Nationwide Population-based Longitudinal Cohort Study." Clinical Epidemiology, vol. 10, 2018, pp. 159-165.
Lin TK, Liou YS, Lin CH, et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol. 2018;10:159-165.
Lin, T. K., Liou, Y. S., Lin, C. H., Chou, P., & Jong, G. P. (2018). High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clinical Epidemiology, 10, 159-165. https://doi.org/10.2147/CLEP.S145311
Lin TK, et al. High-potency Statins but Not All Statins Decrease the Risk of New-onset Osteoporotic Fractures: a Nationwide Population-based Longitudinal Cohort Study. Clin Epidemiol. 2018;10:159-165. PubMed PMID: 29403315.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. AU - Lin,Tsung-Kun, AU - Liou,Yi-Sheng, AU - Lin,Ching-Heng, AU - Chou,Pesus, AU - Jong,Gwo-Ping, Y1 - 2018/01/18/ PY - 2018/2/7/entrez PY - 2018/2/7/pubmed PY - 2018/2/7/medline KW - hyperlipidemia KW - new-onset osteoporosis fracture KW - statins SP - 159 EP - 165 JF - Clinical epidemiology JO - Clin Epidemiol VL - 10 N2 - Background: Statins have been linked to new-onset osteoporotic fractures (NOFs), and different statins may alter the risk for the development of NOFs. Aim: In this study, we investigated the association between different statins and the development of NOFs. Patients and methods: This was a longitudinal cohort study performed using data from claim forms submitted to the Taiwan Bureau of National Health Insurance, including case patients with NOFs from January 2004 to December 2013 and non-NOF subjects. We estimated the hazard ratios (HRs) of NOFs associated with statin use. Nonuser subjects served as the reference group. Results: A total of 44,405 patients with NOFs were identified from among 170,533 patients with hyperlipidemia during the study period. The risk of developing NOFs after adjusting for age, sex, comorbidities, and concurrent medication use was lower among users of atorvastatin (HR, 0.77; 95% CI, 0.71-0.84) and rosuvastatin (HR, 0.72; 95% CI, 0.64-0.81) than among simvastatin users. Lovastatin, pravastatin, fluvastatin, and pitavastatin were not associated with the risk of developing NOFs compared with simvastatin users. Conclusion: This study supports previous reports regarding a beneficial effect of statin use and NOF risk, but not all statins. Patients taking atorvastatin or rosuvastatin were at lower risk of developing NOFs compared with simvastatin users during the 10-year follow-up. Other statins such as pravastatin, fluvastatin, lovastatin, and pitavastatin were not associated with NOFs. This study also highlighted that high-potency statin has a dose-response effect on lower NOF risk. SN - 1179-1349 UR - https://www.unboundmedicine.com/medline/citation/29403315/High_potency_statins_but_not_all_statins_decrease_the_risk_of_new_onset_osteoporotic_fractures:_a_nationwide_population_based_longitudinal_cohort_study_ L2 - https://dx.doi.org/10.2147/CLEP.S145311 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.